Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes
We report that NAC is well-utilized across Finland, with CR rates comparable to recent trials. Additionally, our survival rates are reasonable, and even with organ-confined residual disease after NAC, survival outcomes are similar to those who underwent RC alone.
Authors
- Mikael Högerman (ORCID: https://orcid.org/0000-0002-4287-9231)
- Ilkka Nikulainen (ORCID: https://orcid.org/0000-0002-6065-4087)
- Heikki Seikkula (ORCID: https://orcid.org/0000-0001-9942-1582)
- Peter J. Boström (ORCID: https://orcid.org/0000-0003-3647-0015)
- Antti Salminen (ORCID: https://orcid.org/0000-0001-6081-7686)
Institutions
- University of Turku (FI)
- Turku University Hospital (FI)
- Central Finland Health Care District (FI)
Publication Details
- Journal
- Cancers
- Published
- 2025-02-03
- DOI
- https://doi.org/10.3390/cancers17030505
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01